For the acute treatment of migraine, rimegepant (Nurtec, Biohaven Pharmaceuticals) significantly outperformed over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs), according to a post hoc analysis of data from two phase 3 trials.
JULY 28, 2020